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Certain autoimmune diseases result in abnormal
bone homeostasis, but association of immunodefi-
ciency with bone is poorly understood. Osteoclasts,
which derive from bone marrow cells, are under the
control of the immune system. Differentiation of oste-
oclasts is mainly regulated by signaling pathways
activated by RANK and immune receptors linked to
ITAM-harboring adaptors. However, it is unclear
how the two signalsmerge to cooperate in osteoclast
differentiation. Here we report that mice lacking
the tyrosine kinases Btk and Tec show severe osteo-
petrosis caused by a defect in bone resorption.
RANK and ITAM signaling results in formation of
a Btk(Tec)/BLNK(SLP-76)-containing complex and
PLCg-mediated activation of an essential calcium
signal. Furthermore, Tec kinase inhibition reduces
osteoclastic bone resorption in models of osteopo-
rosis and inflammation-induced bone destruction.
Thus, this study reveals the importance of the osteo-
clastogenic signaling complex composed of tyrosine
kinases, which may provide the molecular basis for
a new therapeutic strategy.794 Cell 132, 794–806, March 7, 2008 ª2008 Elsevier Inc.INTRODUCTION
Bone homeostasis depends on balanced action of bone-resorb-
ing osteoclasts and bone-forming osteoblasts (Karsenty and
Wagner, 2002). Tipping the balance in favor of osteoclasts leads
to diseases with a low bone mass, whereas impaired osteoclas-
tic bone resorption results in diseases with a high bone mass,
including osteopetrosis (Teitelbaum and Ross, 2003). Bone re-
serves calcium and responds to calcium-regulating hormones,
but osteoclasts and osteoblasts are not only regulated by the en-
docrine system. The immune and bone systems share numerous
regulatory factors, including cytokines, receptors, signaling mol-
ecules, and transcription factors (Theill et al., 2002; Walsh et al.,
2006; Takayanagi, 2007). Therefore, the pathology of one system
may very well affect the other: it is well documented that en-
hanced bone resorption is associated with activation of the im-
mune system observed in autoimmune or inflammatory diseases
such as rheumatoid arthritis and periodontitis (Theill et al., 2002;
Takayanagi, 2007).
Diseases with impaired immune responses are also associ-
ated with bone abnormalities, but it is poorly understood how
the immunodeficiencies are functionally related to bone disor-
ders. Hyperimmunoglobulin E (IgE) syndrome is characterized
by skeletal symptoms such as osteoporosis (Kirchner et al.,
1985) and scoliosis (Grimbacher et al., 1999), which are partly
explained by the abnormality of osteoblasts and osteoclasts
caused by the mutation in the STAT3 gene. (Minegishi et al.,
2007). X-linked hyper-IgM syndrome (caused by a mutation in
the CD40L gene) has a skeletal complication, osteopenia, which
is attributed to enhanced osteoclast formation due to the im-
paired production of interferon-g by T cells (Lopez-Granados
et al., 2007). Thus, exploring the mechanisms underlying skeletal
complications in primary immunodeficiencies will be important
for understanding the shared mechanisms and crosstalk be-
tween immune and bone systems.
The osteoclast was the first skeletal cell to be determined to be
under the control of the immune system (Horton et al., 1972). Be-
cause osteoclasts originate from bone marrow-derived mono-
cyte/macrophage precursor cells (BMMs) of hematopoietic line-
age, many regulators of osteoclast differentiation are also utilized
in the control of the innate and adaptive immune systems. The dif-
ferentiation of osteoclasts is mainly regulated by three signaling
pathways activated by receptor activator of nuclear factor-kB li-
gand (RANKL), macrophage colony-stimulating factor (M-CSF),
and immunoreceptor tyrosine-based activation motif (ITAM)
(Asagiri and Takayanagi, 2007). Whereas M-CSF promotes the
proliferation and survival of BMMs (Ross and Teitelbaum,
2005), RANKL activates the differentiation process by inducing
the master transcription factor for osteoclastogenesis, nuclear
factor of activated T cells c1 (NFATc1), via the tumor necrosis fac-
tor receptor-associated factor 6 (TRAF6) and c-Fos pathways
(Takayanagi et al., 2002). The induction of NFATc1 is also depen-
dent on the calcium signal, which is mediated by the activation of
ITAM in adaptor molecules such as DNAX-activating protein 12
(DAP12) and Fc receptor common g subunit (FcRg) (Koga et al.,
2004; Mocsai et al., 2004) in association with costimulatory re-
ceptors of the immunoglobulin superfamily, including triggering
receptor expressed in myeloid cells-2 (TREM-2), signal-regula-
tory protein b1 (SIRPb1), paired immunoglobulin-like receptor-A
(PIR-A), and osteoclast-associated receptor (OSCAR) (Koga
et al., 2004). Phosphorylation of ITAM results in recruitment of
the nonreceptor tyrosine kinase Syk, leading to the activation of
phospholipase Cg (PLCg) and calcium mobilization (Faccio
et al., 2003; Koga et al., 2004; Mocsai et al., 2004; Mao et al.,
2006), but osteoclastogenesis cannot be induced by costimula-
tory signals alone and requires RANKL stimulation. However, it
has been unclear how RANK and ITAM signals merge to cooper-
atively stimulate the downstream signaling pathway.
To identify the molecules activated by RANKL that stimulate
the calcium signaling pathway by functioning as an integrator
of the RANK and ITAM signals, we focused on nonreceptor tyro-
sine kinases because PLCg initiates the calcium signal after tyro-
sine phosphorylation. Among the nonreceptor tyrosine kinases,
genome-wide screening revealed Btk and Tec to be highly
expressed in osteoclasts. The Tec kinase family, consisting of
Bmx, Btk, Itk, Rlk, and Tec, is preferentially expressed in the he-
matopoietic system. T cell receptor (TCR) and B cell receptor
(BCR) signaling complexes include Itk/Rlk and Tec/Btk, respec-
tively (Schmidt et al., 2004). The role of Btk in antibody produc-
tion is well recognized by the existence of immunodeficiencies,
X-linked agammaglobulinemia (XLA) in humans (Tsukada et al.,
1993) and X-linked immunodeficiency (Xid) in mice (Kerner
et al., 1995), caused by a mutation in the Btk gene; in addition,
mice with a combined deficiency of Tec family kinases displayboth unique and redundant functions in B cells (Btk and Tec) (Ell-
meier et al., 2000) and T cells (Itk and Rlk) (Schaeffer et al., 1999).
Here we report the crucial role of Btk and Tec in RANKL-induced
osteoclastogenesis based on the genetic evidence obtained
from Tec/Btk/ mice. In response to RANKL stimulation,
Btk and Tec kinases form a signaling complex required for osteo-
clastogenesis with adaptor molecules such as BLNK, which also
recruits Syk, thus linking the RANK and ITAM signals to phos-
phorylate PLCg. This study provides a clear example of immuno-
deficiency association with abnormal bone homeostasis owing
to defects in signaling molecules shared by B cells and osteo-
clasts. Moreover, therapeutic models suggest that suppression
of Tec kinases can serve as a molecular basis for the develop-
ment of future therapeutic strategies against bone diseases.
RESULTS
Osteoclasts Selectively Express Btk
and Tec among Tec Kinases
RANK and ITAM signals cooperate to induce calcium signaling,
but it has been unknown how these two signals are integrated.
To gain insight into the molecules activated by RANKL that are
potentially involved in the activation of tyrosine phosphorylation
of the PLCg pathway, we performed a genome-wide screening
of mRNAs for nonreceptor tyrosine kinases expressed during os-
teoclast and osteoblast differentiation (Figure 1A). We identified
high expression of Src and Syk, whose crucial functions in the os-
teoclast lineage have been well documented (Soriano et al., 1991;
Faccio et al., 2003; Koga et al., 2004). Interestingly, osteoclasts,
butnotosteoblasts,express themRNAs forBtkandTecatahigher
level than that for Src (Figure 1A). The selective expression of
Btk and Tec in osteoclast precursor cells was also confirmed by
RT-PCR (Figure 1B) and immunoblot analysis (Figure 1C).
Osteopetrotic Phenotype of Mice Doubly
Deficient in Btk and Tec
The results led us to analyze the bone phenotype of mice defi-
cient in Tec (Ellmeier et al., 2000), Btk (Kerner et al., 1995), or
both (Ellmeier et al., 2000). Microradiological analysis revealed
the trabecular bone volume to be normal in Tec/ mice, mini-
mally increased in Btk/ mice, and markedly increased in
Tec/Btk/ mice (Figure 1D). Microcomputed tomography
clearly indicated that the bone volume was greatly enhanced in
Tec/Btk/ mice (Figure 1E). Histological analysis revealed
the osteoclast number was significantly reduced in the epiphy-
seal region, and the bone marrow was abnormally filled with
trabecular bone in Tec/Btk/ mice (Figure 1F). We also ob-
served cartilage remnants characteristic of osteopetrosis in
Tec/Btk/ mice (Figure 1F). Bone morphometric analysis in-
dicated an increase in bone volume associated with a reduced
osteoclast number, a decrease in the indicators of osteoclastic
bone resorption (Figure 1G), and a normal level of bone formation
in Tec/Btk/mice (Figure 1H). There was no significant differ-
ence in the resorption and formation parameters among the wild-
type (WT), Tec/, and Btk/ mice (see Figure S1 available on-
line). These results collectively suggest that the increase in bone
mass in Tec/Btk/ mice is caused by impaired osteoclastic
bone resorption owing to a defect in osteoclast differentiation.Cell 132, 794–806, March 7, 2008 ª2008 Elsevier Inc. 795
Figure 1. Osteopetrotic Phenotype of Tec/Btk/ Mice
(A) GeneChip analysis of mRNAs for nonreceptor tyrosine kinases during osteoclast and osteoblast differentiation. FAK, focal adhesion kinase; Fes, feline
sarcoma oncogene; Csk, c-src tyrosine kinase.
(B) RT-PCR analysis of Tec, Btk, and Itk mRNAs in WT and Tec/Btk/ BMMs.
(C) Expression of Tec, Btk, and Itk proteins in WT and Tec/Btk/ BMMs.796 Cell 132, 794–806, March 7, 2008 ª2008 Elsevier Inc.
Figure 2. Crucial Role of Tec Family Kinases in RANKL-Induced Osteoclast Differentiation
(A) Osteoclast differentiation from WT, Tec/, Btk/, and Tec/Btk/ BMMs in response to RANKL and M-CSF.
(B) Cell proliferation rate (BrdU incorporation assay) and apoptosis (TUNEL assay) of WT and Tec/Btk/ BMMs stimulated with RANKL and M-CSF.
(C) NFATc1 induction in WT and Tec/Btk/BMMs 72 hr after RANKL stimulation. Retroviral introduction of Btk into Tec/Btk/BMMs recovers the NFATc1
induction.
(D) Effect of the Tec kinase inhibitor LFM-A13 on the osteoclast differentiation induced by RANKL and M-CSF.
(E) Phosphorylation of Btk and Tec in BMMs in response to RANKL.Despite the severe defect in osteoclastic bone resorption, the
Tec/Btk/ mice had normal tooth eruption, but the results
nevertheless suggest that the two kinases play a critically impor-
tant role in osteoclast differentiation.
Btk and Tec Are Activated by RANKL and Indispensable
for Osteoclastogenesis
In vitro osteoclast differentiation was evaluated by counting the
multinucleated cells (MNCs) positive for the osteoclast marker
tartrate-resistant acid phosphatase (TRAP) after stimulation of
BMMs with recombinant RANKL in the presence of M-CSF. Os-
teoclast differentiation was only minimally affected in Tec/
cells but was severely impaired in Btk/ cells and almost
completely abrogated in Tec/Btk/ cells (Figure 2A). Therewas no significant difference in M-CSF-dependent proliferation
of precursor cells or the rate of apoptosis between WT and
Tec/Btk/ cells (Figure 2B) or in the number of CD11b+ cells
in the M-CSF-stimulated bone marrow cells (data not shown).
Therefore, there is no defect in the generation of osteoclast pre-
cursor cells in Tec/Btk/mice, although we observed that the
survival of mature macrophages derived from Tec/Btk/
mice was partly impaired when cultured with a low concentration
of M-CSF (W.E., unpublished data). RANKL-stimulated induction
of NFATc1, the key transcription factor for osteoclastogenesis,
was severely suppressed in Tec/Btk/ cells (Figure 2C) and
Btk/ cells (data not shown). We also analyzed the effect of
the Tec kinase inhibitor LFM-A13 (Mahajan et al., 1999), which
was designed to specifically bind the ATP-binding site of Btk,(D) Microradiograph of the femur of WT, Tec/, Btk/, and Tec/Btk/ mice.
(E) Microcomputed tomography of the epiphyseal region of the femurs of WT and Tec/Btk/ mice.
(F) Histological analysis of the proximal tibiae of WT and Tec/Btk/ mice (upper, TRAP/hematoxylin; lower, toluidine blue stainings). Note that the number
of TRAP-positive cells is markedly decreased in Tec/Btk/ mice. The bone marrow is filled with unresorbed bone, in which cartilage remnants (arrowheads)
characteristic of osteopetrosis are observed.
(G and H) (G) Bone volume and parameters for osteoclastic bone resorption and (H) parameters for osteoblastic bone formation in the bone morphometric
analysis of WT and Tec/Btk/ mice. *p < 0.05; **p < 0.01; ***p < 0.005; n.s., not significant (throughout the paper).Cell 132, 794–806, March 7, 2008 ª2008 Elsevier Inc. 797
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and which was revealed subsequently to suppress other Tec
kinases additionally (Fernandes et al., 2005), on osteoclast differ-
entiation. LFM-A13 strongly inhibited RANKL-induced osteo-
clastogenesis (Figure 2D) and NFATc1 induction (data not
shown). In contrast, this compound only slightly affected the
bone resorption activity of osteoclasts (Figure S2). Importantly,
phosphorylation of Btk and Tec was induced by RANKL stimula-
tion in BMMs (Figure 2E). Thus, the tyrosine kinases Btk and Tec
are activated by RANKL and play a crucial role in RANKL-
induced signal transduction during osteoclastogenesis.
Impaired Osteoclastogenesis in Tec/Btk/ Mice
Caused by a Cell-Autonomous Mechanism
To determine whether impaired osteoclastogenesis in Tec/
Btk/ mice is caused by a cell-autonomous mechanism, we
evaluated the osteoclastogenesis in the coculture system of
bone marrow cells with osteoblasts. In the coculture of bone
marrow cells derived from mutant mice with WT osteoblasts, os-
teoclast formation was not severely affected in Tec/ or Btk/
cells but was almost abrogated in Tec/Btk/ cells (Figure 3A).
In contrast, Tec/Btk/ osteoblasts were normally able to sup-
port osteoclastogenesis of WT bone marrow cells (Figure 3B).
These results suggest that the impaired osteoclastogenesis in
Tec/Btk/ mice is caused by a defect in osteoclast precursor
cells. Consistent with the observation that the Btk/ mice have
a normal number of osteoclasts in vivo (Figure S1), Btk/ cells
differentiate into osteoclasts in the coculture system essentially
in a normal manner (Figure 3A), indicating that the larger contri-
bution of Btk is observed only under limited in vitro conditions,
including the RANKL/M-CSF-stimulated BMM culture system
(Figure 2A). Since a similar observation has been made in
DAP12/ cells (Koga et al., 2004), we infer that Btk is more
closely associated with the DAP12-dependent pathway.
SinceTec/Btk/mice have almost no B cells and exhibit se-
vere immunodeficiency (but their T cells are not affected) (Ellmeier
et al., 2000), it is possible that the impaired osteoclastogenesis is
influenced by differences in the B cell number in the bone marrow.
Therefore, we examined whether depletion or addition of CD19+
B cells had any effect on osteoclastogenesis from bone marrow
cells containing B cells. Osteoclast differentiation was not influ-
enced by the coexistence of B cells in either WT or Tec/Btk/
cells (Figure 3C). Taken together, these results indicate that the
impaired osteoclastogenesis in Tec/Btk/ mice is not related
to an abnormality of other cell types such as osteoblasts or B
cells, supporting the notion that the impaired osteoclast differen-
tiation is caused by a cell-autonomous mechanism.
Consistent with this notion, retrovirus-mediated expression of
Btk and Tec almost completely recovered the osteoclast differ-
entiation in Tec/Btk/ BMMs. The introduction of Btk intoTec/Btk/ BMMs by retroviral transfer markedly rescued
the differentiation blockade, but that of Tec rescued it to a lesser
extent (Figure 3D). This result is consistent with the dominant
role of Btk in osteoclastogenesis in the BMM culture system
(Figure 2A). Tec family kinases contain a pleckstrin-homology
(PH) domain that binds to phosphatidylinositol-3,4,5-triphos-
phate (PtdIns[3,4,5]P3), a lipid product of phosphoinositide 3-ki-
nase, a Tec homology domain, and a carboxyl-terminal kinase
domain (Schmidt et al., 2004). A kinase-inactive mutant of Btk
(R525Q) that carries a mutation in the kinase domain (Takata
and Kurosaki, 1996) did not rescue the osteoclast differentiation
blockade, but another mutant (R28C) that harbors a mutation in
the PH domain (Takata and Kurosaki, 1996), which causes a cer-
tain type of XLA in humans (Tsukada et al., 1993), exhibited a
capacity for rescue comparable to the WT Btk (Figure 3E). The
results suggest that the function of Btk in osteoclastogenesis
requires its kinase activity but does not completely depend on
the interaction with PtdIns(3,4,5)P3 through the PH domain.
Tec Kinases Link the RANK Signal
to the Phosphorylation of PLCg
How does deficiency of Btk and Tec affect the osteoclastogenic
signaling pathways? To address these issues by a systems biol-
ogy approach, we utilized a systematic protein-protein interac-
tion database created by the Genome Network Project (http://
genomenetwork.nig.ac.jp/index.html), in which our laboratory
has served as a working member. From this database, we ex-
tracted the protein-protein interaction network related to the
two major signaling pathways regulating osteoclastogenesis,
the RANK and ITAM pathways, with which we merged our orig-
inal data on the increase in mRNA expression after RANKL stim-
ulation (Figure 4A). The RANK-associated gene network in-
cluded TRAF6, NF-kB, and mitogen-activated protein kinase
(MAPK), whereas the ITAM (DAP12/FcRg)-associated gene net-
work included Syk, PLCg, and Btk/Tec. As expected, the ex-
pression of many RANK-associated molecules was upregulated
by RANKL stimulation. Interestingly, the expression of many
of the genes in the ITAM-associated gene network was also
upregulated by RANKL stimulation.
Based on these results, together with the observation that Btk
and Tec were activated by RANKL (Figure 2E), we hypothesized
that Btk and Tec are the molecules that bridge the RANK and
ITAM pathways to activate calcium signaling. Notably, RANKL-
induced tyrosine phosphorylation of PLCg1 and PLCg2 was
markedly suppressed in Tec/Btk/ cells (Figure 4B). Further-
more, the RANKL-induced calcium oscillation required for
NFATc1 induction was barely observed in Tec/Btk/ cells
(Figure 4C). In contrast, we observed a normal level of RANKL-in-
duced activation of MAPKs (ERK, JNK, p38), IkB kinase a (IKKa),Figure 3. Impaired Osteoclastogenesis in Tec/Btk/ Mice Caused by a Cell-Autonomous Mechanism
(A) Osteoclast differentiation from WT, Tec/, Btk/, and Tec/Btk/ bone marrow cells in the coculture system with WT osteoblasts.
(B) Osteoclast differentiation from WT bone marrow cells in the coculture system with WT or Tec/Btk/ osteoblasts.
(C) Effect of CD19+ B cell depletion on osteoclast differentiation. The number of CD19+ cells before and after depletion of CD19+ B cells in bone marrow cells
derived from WT or Tec/Btk/ mice (left). Osteoclast differentiation from WT and Tec/Btk/ BMMs after depletion of CD19+ B cells in response to RANKL
and M-CSF (right).
(D) Effects of retroviral expression of Tec (pMX Tec) and/or Btk (pMX Btk) on osteoclastogenesis from Tec/Btk/ BMMs stimulated with RANKL and M-CSF.
(E) Effects of retroviral expression of WT Btk or Btk mutants harboring a mutation in the PH domain (R28C) or the kinase domain (R525Q) on osteoclastogenesis
from Tec/Btk/ BMMs stimulated with RANKL and M-CSF.Cell 132, 794–806, March 7, 2008 ª2008 Elsevier Inc. 799
Figure 4. Tec Kinases Mediate Osteoclastogenic Signaling Pathway
(A) Dynamic protein-protein interaction network in osteoclast differentiation. Proteins connected with a black line are interacting partners, and the color indicates
how many fold mRNA expression was increased 24 hr after RANKL stimulation.
(B) RANKL-induced PLCg1 and PLCg2 phosphorylation in WT and Tec/Btk/ BMMs.
(C) Oscillatory change in the intracellular Ca2+ concentration in WT and Tec/Btk/BMMs after RANKL stimulation. The addition of 10 mM ionomycin at the end
of each experiment is indicated by an arrow. Each color indicates a different cell in the same field.
(D) RANKL-induced ERK, JNK, p38, Akt, and IKK phosphorylation in WT and Tec/Btk/ BMMs.IKKb, and Akt, all of which are activated downstream of TRAF6
(Wong et al., 1999) (Figure 4D). These results indicate that
RANKL-activated Btk and Tec are selectively involved in the
phosphorylation of PLCg, and a defect in calcium signaling
causes the impaired NFATc1 induction in Tec/Btk/ cells.
Thus, Btk and Tec link the RANK signal to calcium signaling in
the osteoclast lineage.
Tec Kinases Form an Osteoclastogenic
Signaling Complex with Scaffold Proteins
Since PLCg activation is known to be dependent on the ITAM
signal, another question arises as to how PLCg activation is reg-
ulated by both RANK and ITAM signals. The ITAM-associated800 Cell 132, 794–806, March 7, 2008 ª2008 Elsevier Inc.gene network indicates that ITAM associates with Syk, which
associates with and phosphorylates scaffold proteins such as
BLNK (Ishiai et al., 1999). Because BLNK associates with Btk
in a phosphorylation-dependent manner in B cells (Hashimoto
et al., 1999), we examined whether RANKL-activated Btk is re-
cruited to BLNK in BMMs. The colocalization of Btk and BLNK
was increased, at what appeared to be the plasma membrane,
after RANKL stimulation (Figure 5A and Figure S3). This translo-
cation was not observed in DAP12/FcRg/ cells (Figure 5A
and Figure S3), suggesting that the ITAM signals are also re-
quired for the formation of the Btk-BLNK complex. Consistent
with this, immunoblot analysis showed that Btk coimmunopreci-
pitated with BLNK in BMMs in the presence of RANKL, but
Figure 5. Tec Kinases Form an Osteoclastogenic Signaling Complex with Scaffold Proteins
(A) Immunofluorescence microscopic analysis of colocalization of Btk and BLNK in WT and DAP12/FcRg/ cells 15 min after RANKL stimulation. The nuclei
were stained with Hoechst 33342.
(B) Immunoprecipitation analysis of the interaction between Btk and BLNK in WT and DAP12/FcRg/ cells 15 min after RANKL stimulation.
(C) Tyrosine phosphorylation of Tec kinases in WT and DAP12/FcRg/ cells 15 min after RANKL stimulation.
(D) Expression of CD11b in the M-CSF-stimulated bone marrow cells from WT and Blnk/Lcp2/ mice (flow cytometry).
(E) Cell proliferation rate (BrdU incorporation assay) and apoptosis (TUNEL assay) of WT and Blnk/Lcp2/ BMMs stimulated with RANKL and M-CSF.
(F) Osteoclast differentiation from WT and Blnk/Lcp2/ BMMs in response to RANKL and M-CSF.the association was abrogated in DAP12/FcRg/ cells (Fig-
ure 5B). Furthermore, Tec kinases were phosphorylated in re-
sponse to RANKL, even in DAP12/FcRg/ cells (Figure 5C).
Thus, the activation of Btk by RANK and the activation of
BLNK by the ITAM signal are both required for the association
of Btk with BLNK, which may function as the molecular switch
that integrates RANK and ITAM signals.
To further investigate the role of BLNK in osteoclastogenesis,
we analyzed osteoclast differentiation in BMMs derived from
Blnk/mice (Hayashi et al., 2003). However, there was no signif-
icant difference in RANKL-induced osteoclastogenesis betweenthe WT and Blnk/ cells (data not shown), suggesting that
another molecule(s) compensates for the loss of BLNK. SLP-76
(encoded by Lcp2) is an adaptor protein homologous to BLNK,
functioning mainly in T cells (Pivniouk and Geha, 2000). Since
there was no significant difference in RANKL-induced osteoclas-
togenesis between the WT and Lcp2/ cells (data not shown),
we analyzed mice doubly deficient in BLNK and SLP-76 (Blnk/
Lcp2/ mice). Although Blnk/ mice frequently develop acute
leukemia (Jumaa et al., 2003), there was a normal number of
CD11b+ osteoclast precursor cells in the M-CSF-stimulated
bone marrow cells from Blnk/Lcp2/ mice (Figure 5D), andCell 132, 794–806, March 7, 2008 ª2008 Elsevier Inc. 801
802 Cell 132, 794–806, March 7, 2008 ª2008 Elsevier Inc.
the rate of proliferation or apoptosis in Blnk/Lcp2/ BMMs
was not significantly different from that in WT BMMs
(Figure 5E). We found that in vitro osteoclast differentiation was
severely abrogated in Blnk/Lcp2/ BMMs (Figure 5F), sug-
gesting an important role for BLNK and SLP-76 in osteoclast
differentiation. Thus, the scaffold proteins, with which the Tec
kinases form a complex, have emerged as critical mediators of
osteoclastogenic signals. These results further lend support to
the crucial role of the RANKL-stimulated formation of the osteo-
clastogenic complex: the interaction of Tec kinases and their
scaffold proteins results in the efficient phosphorylation of PLCg.
Tec Kinases as Potential Therapeutic
Targets for Bone Diseases
To investigate the role of Btk and Tec in the pathological activa-
tion of osteoclastogenesis, Tec/Btk/ mice were subjected
to an ovariectomy (OVX)-induced model of postmenopausal os-
teoporosis (Aoki et al., 2006). The bone volume and trabecular
bone number/connectivity were significantly reduced by the es-
trogen withdrawal in WT mice, but such a reduction was ob-
served to a much lesser extent in Tec/Btk/ mice (Figure 6A
and Figure S4). An increase in osteoclast number induced by
OVX was also much lower in Tec/Btk/ mice (Figure 6A and
Figure S4), suggesting a key role of Btk and Tec in the patholog-
ical activation of osteoclastogenesis.
Furthermore, Tec/Btk/ mice were subjected to a lipopoly-
saccharide (LPS)-induced model of inflammatory bone destruc-
tion (Takayanagi et al., 2000). Tec/Btk/ mice were protected
from the activation of osteoclastogenesis and bone loss
(Figure 6B), whereas the formation of an inflammatory cell layer,
the number of infiltrated inflammatory cells, IKK activation, and se-
rum levels of TNF-a and IL-6 in Tec/Btk/mice were not differ-
ent from those in WT mice (Figure 6B and Figure S5). These results
prompted us to examine the therapeutic effects of Tec kinase in-
hibitor in disease models. Local administration of the Tec kinase
inhibitor LFM-A13 had a marked therapeutic effect on the exces-
sive osteoclast formation and bone destruction induced by LPS
(Figure 6C) without affecting IKK activation or inflammatory cyto-
kine levels in the serum (Figure S5), although it has been reported
that Tec kinases are involved in the activation of immune cells, in-
cluding lymphocytes and macrophages (Horwood et al., 2003;
Mangla et al., 2004). These results suggest that the therapeutic ef-
fects of Tec kinase inhibitor in an LPS-induced model are not due
to attenuated immune responses but rather are mainly caused by
direct inhibitory effects on osteoclast precursor cells. It has been
consistently reported that Btk is not essential for LPS-induced
inflammatory cytokine production in macrophages under certain
conditions (Hata et al., 1998; Perez de Diego et al., 2006).To determine whether the Tec kinase inhibitor has therapeutic
efficacy in a model of osteoporosis, we treated mice that were
intraperitoneally injected with GST-RANKL. GST-RANKL injec-
tion resulted in an increase in osteoclast number and serum cal-
cium concentration and a decrease in trabecular bone volume,
but LFM-A13 treatment significantly ameliorated RANKL-
induced bone loss (Figure 6D). These results demonstrate the
inactivation of Tec family kinases to be a novel strategy for
suppressing osteoclastogenesis in vivo.
DISCUSSION
RANKL-Induced Formation of the Osteoclastogenic
Signaling Complex
An osteopetrotic phenotype in Tec/Btk/ mice revealed
these two kinases to play a crucial role in the regulation of oste-
oclast differentiation. Btk and Tec are known to play a key role in
proximal BCR signaling (Ellmeier et al., 2000), but this study
establishes their crucial role in the integration of the two essen-
tial osteoclastogenic signals, RANK and ITAM (Figure 7). Thus,
although immune and bone cells share components of signaling
cascades, they play distinct roles in each cell type. Furthermore,
this study identified an osteoclastogenic signaling complex
composed of Tec kinases and adaptor proteins that may pro-
vide a new paradigm for the signal transduction mechanism of
osteoclast differentiation: ITAM phosphorylation results in the
recruitment of Syk, which phosphorylates adaptor proteins
such as BLNK and SLP-76, which in turn function as scaffolds
to recruit the Tec kinases activated by RANK and PLCg to the
osteoclast signaling complex so as to induce maximal calcium
influx.
Such complexes are similar to those formed in the immunolog-
ical synapse in T cells, which are associated with membrane
rafts (Cherukuri et al., 2001). It has been reported that RANK ac-
cumulates in membrane rafts, and these specialized domains
may play an important role in the RANK signal transduction (Ha
et al., 2003). We observed that DAP12, Btk, BLNK, and PLCg,
as well as RANK, were recruited to caveolin-rich membrane do-
mains, which are the crucial signaling domains contained in lipid
rafts, after RANKL stimulation (Figure S6). Thus, it is likely that the
complex containing both the RANK and ITAM signaling path-
ways is generated by RANKL stimulation and contributes to
the facilitation of the osteoclastogenic signal transduction.
Linkage between Primary Immunodeficiency
and Bone Homeostasis
The mutation of Btk in humans causes XLA, which is character-
ized by an arrest in B cell development and immunodeficiencyFigure 6. Tec Kinases as Potential Therapeutic Targets in Bone Diseases
(A) OVX-induced bone loss in WT and Tec/Btk/ mice (evaluated in the femurs and tibiae 3 weeks after sham operation or OVX). The trabecular thickness,
separation, and number were obtained from three-dimensional microstructural analysis by microcomputed tomography. Bone volume, osteoclast number, and
eroded surface were based on the bone morphometric analysis.
(B) Inflammation-induced bone destruction in WT and Tec/Btk/ mice. Histology of the calvarial bone injected with saline (control) or LPS in WT and Tec/
Btk/ mice (TRAP and hematoxylin staining).
(C) Effect of local administration of the Tec kinase inhibitor LFM-A13 (20 mg/kg) on LPS-induced osteoclast formation and bone destruction (TRAP and hema-
toxylin staining). This inhibitor at this dosage had marginal effects on B cells.
(D) Effect of local administration of LFM-A13 (20 mg/kg) on RANKL-induced osteoclast formation and bone loss. After mice were sacrificed 1.5 hr after the final
injection, serum calcium level was measured, and three-dimensional microstructural analysis (femur) and the bone morphometric analysis (tibia) were performed.Cell 132, 794–806, March 7, 2008 ª2008 Elsevier Inc. 803
(Tsukada et al., 1993). Targeted disruption of Btk alone did not
result in an obvious bone phenotype in mice, and B cell immuno-
globulin production was also not severely affected in this strain
(Kerner et al., 1995). Therefore, it is possible that the mouse
and human utilization of Tec family kinases is not strictly the
same. Because immunoglobulin production is completely abro-
gated in the combined deficiency of Btk and Tec (Ellmeier et al.,
2000), Tec/Btk/ mice may serve as a better model of XLA.
Currently there is no report on abnormalities of bone metabolism
in the XLA patients, but it will be of great significance to analyze
bone density and quality in patients with primary immunodefi-
ciencies in the future. These studies, together with others, in-
cluding recent data on hyper-IgM syndrome (Lopez-Granados
et al., 2007), will surely shed light on unexpected aspects of
the linkage between the immune and bone systems.
Upstream and Downstream of Tec Kinases
in the Osteoclastogenic Signal Transduction
Although phosphorylation of Tec kinases is dependent on Src
family kinases in immune cells (Schmidt et al., 2004), c-Src defi-
ciency or inhibition of Src family kinases by PP2 has little effect
on osteoclast differentiation (T.K. and H.T., unpublished data).
Although it is possible that other Src family members may
compensate, to date there has been no clear evidence demon-
strating an essential role for Src kinases in osteoclast differenti-
ation; therefore, the kinases that phosphorylate the Tec kinases
in osteoclasts remain to be elucidated.
Based on the in vitro data (Figure 4B), the phosphorylation of
PLCg by RANKL is mostly dependent on Btk and Tec. However,
Figure 7. Integration of the RANK and ITAM Signals by Tec Kinases
RANKL binding to RANK results in activation of classical pathways involving
TRAF6 and c-Fos. In addition, Tec kinases are phosphorylated by RANK.
ITAM phosphorylation results in the recruitment of Syk, leading to activation
of adaptor proteins such as BLNK and SLP-76, which function as scaffolds
that recruit both Tec kinases and PLCg to form the osteoclastogenic signaling
complex. This complex is crucial for efficient activation of calcium signaling
required for the induction and activation of NFATc1, the key transcription
factor for osteoclast differentiation.804 Cell 132, 794–806, March 7, 2008 ª2008 Elsevier Inc.osteopetrosis in Tec/Btk/ mice is less severe than that in
DAP12/FcRg/ mice, and pathological bone loss is not com-
pletely abrogated in the Tec/Btk/ mice or the Tec kinase
inhibitor-treated mice. It is conceivable that the loss of Btk and
Tec is partly compensated by other Tec kinases or that an alter-
native kinase(s) partially functions as a PLCg kinase during
osteoclastogenesis.
Despite the crucial role of BLNK and SLP-76 in osteoclast
differentiation in vitro, bone mineral density was not markedly
increased in Blnk/Lcp2/ mice (M.S., T.K., and H.T., unpub-
lished data). One explanation for this discrepancy is that BLNK
and SLP-76 do play a substantially important role, but another
adaptor molecule, such as cytokine-dependent hematopoietic
cell linker (Clnk), may compensate for the loss in vivo. Although
further studies are necessary to elucidate the mechanism(s), it
is likely that membrane-bound or soluble factors, which induce
or activate Clnk, are compensatorily upregulated only in vivo.
In addition, as Blnk/Lcp2/ mice develop acute leukemia at
a very high frequency (more than 90%; D.K., unpublished
data), the onset of acute leukemia may affect bone homeostasis
by producing soluble factors that activate osteoclastogenesis or
inhibit osteoblastic bone formation.
Tec Family Kinases as Therapeutic Targets
for Bone Diseases
Tec/Btk/ mice are resistant to OVX-induced bone loss, but
DAP12/FcRg/ mice, which exhibit more severe osteopet-
rosis, do lose bone after OVX in certain bones (Wu et al.,
2007). These results suggest that osteoclastogenesis under
pathological conditions is dependent on a signaling mechanism
distinct from that in physiological bone remodeling. Whatever
the detailed mechanism, the results indicate that the Tec
kinases offer some auspicious therapeutic targets in the treat-
ment of metabolic and inflammatory bone diseases (see
Figure 6).
Considering the severe immunodeficiency in XLA, careful at-
tention would obviously have to be given to side effects on
other cell types, including B cells, if Tec kinases were system-
ically inhibited in order to treat metabolic bone diseases. In the
case of inflammatory bone diseases such as rheumatoid arthri-
tis, certain immunosuppressants have already been success-
fully utilized in the clinic, so the inhibition of these kinases
may prove to be a potentially effective strategy for preventing
bone destruction associated with inflammation. Undoubtedly,
the suppression of molecules shared by immune and bone cells
will require a very careful evaluation in both systems prior to
any clinical application, but these efforts will be rewarded by
the provision of a molecular basis for novel drug design in
the future.
EXPERIMENTAL PROCEDURES
Mice and Analysis of Bone Phenotype
We previously described the generation of Tec/Btk/ (Ellmeier et al., 2000)
and DAP12/FcRg/ (Koga et al., 2004) mice. Blnk/ (Hayashi et al., 2003)
and Lcp2/ (Pivniouk et al., 1998) mice were described previously. Histomor-
phometric and microradiographic examinations were performed as described
(Koga et al., 2004).
In Vitro Osteoclast Formation, Ca2+ Measurement,
and GeneChip Analysis
Bone marrow cells were cultured with 10 ng/ml M-CSF (R & D Systems) for 2
days, and they were used as BMMs. BMMs were cultured with 50 ng/ml
RANKL (Peprotech) and 10 ng/ml M-CSF for 3 days. RANKL and M-CSF
were added at these concentrations unless otherwise indicated. In the cocul-
ture system, bone marrow cells were cultured with calvarial osteoblasts with
108 M 1,25-dihydroxyvitamin D3 and 10
6 M prostaglandin E2. TRAP-positive
MNCs (TRAP+ MNCs, more than three nuclei) were counted. Proliferation rate
was determined 24 hr after RANKL stimulation using Cell Proliferation ELISA
Kit (Roche). Apoptosis was assayed 24 hr after RANKL stimulation using In
Situ Cell Death Detection Kit (Roche). In Figure 2D, LFM-A13 (Calbiochem)
was added at the same time as RANKL. Concentration of intracellular calcium
was measured and GeneChip analysis was performed as described (Takaya-
nagi et al., 2002).
Retroviral Gene Transfer
Retroviral vectors, pMX-Tec-IRES-GFP, pMX-Btk-IRES-GFP, pMX-Btk
(R28C)-IRES-GFP, and pMX-Btk (R525Q)-IRES-GFP, were constructed by in-
serting cDNA fragments of Tec, Btk, Btk (R28C), or Btk (R525Q) (Takata and
Kurosaki, 1996) into pMX-IRES-EGFP. Retrovirus packaging was performed
by transfecting Plat-E cells with the plasmids as described previously (Morita
et al., 2000). After 6 hr inoculation, BMMs were stimulated with RANKL for
3 days.
Depletion of CD19+ B Cells
Bone marrow cells contain CD19+ cells at the ratio of about 30% in WT mice
and about 15% in Tec/Btk/ mice. CD19+ cells were depleted with a mag-
netic sorter and anti-CD19 microbeads (MACS; Miltenyi Biotec). The purity
was confirmed by FACS, and the population of CD19+ B cells was less than
5% in these preparations.
Immunoblot Analysis, Immunofluorescence Staining,
and Flow Cytometry
After being stimulated with RANKL and M-CSF, BMMs were harvested and
cell lysates were subjected to immunoblot or immunoprecipitation analyses
with specific antibodies against Tec (Mano et al., 1995), Btk, NFATc1,
PLCg1, BLNK, DAP12, b-actin (Santa Cruz), phospho-PLCg2, PLCg2, phos-
pho-ERK, ERK, phospho-p38, p38, phospho-JNK, JNK, phospho-Akt, Akt,
phospho-IKKa/b, IKKa, IKKb (Cell Signaling), phospho-PLCg1 (Biosource
International), Itk, 4G10 (Upstate), and phospho-Btk (BD Biosciences). For
immunofluorescence staining, cells were fixed with 4% paraformaldehyde,
permeabilized, and then treated with the indicated specific antibodies followed
by staining with Alexa Fluor 488- or 546-labeled secondary antibody (Molecu-
lar Probes). For flow cytometry, bone marrow cells were incubated with the
anti-CD11b antibody (BD Biosciences) or control rat IgG for 30 min followed
by staining with PE-conjugated anti-rat IgG antibody.
Ovariectomy-Induced Bone Loss
Seven-week-old female mice were ovariectomized under anesthesia. Three or
8 weeks after surgery, all of the mice were sacrificed and subjected to histo-
morphometric and microradiographic examinations. Parameters for trabecu-
lar bone (thickness, separation, and number) were calculated on the basis of
data obtained from microcomputed tomography analysis as described (Aoki
et al., 2006).
LPS-Induced Bone Destruction
Seven-week-old female mice were administered with a local calvarial injec-
tion of LPS (Sigma) at 25 mg/kg body weight with a simultaneous injection
of LFM-A13 (20 mg/kg body weight) or saline and were analyzed after
5 days as described (Takayanagi et al., 2000). For the detection of IKK phos-
phorylation, the calvarial tissues were homogenized 15 min after LPS injec-
tion, and lysates were subjected to immunoblot analysis. The serum levels
of TNF-a and IL-6 (30 min after LPS injection) were measured by ELISA kits
(R & D Systems).RANKL-Induced Bone Loss
Seven-week-old C57BL/6 female mice were intraperitoneally injected with
20 mg of GST or GST-RANKL (Oriental Yeast Co., Ltd.) three times at intervals
of 24 hr. LFM-A13 (20 mg/kg body weight) or saline was injected 1 hr prior
to GST-RANKL treatment. One and a half hours after the final injection, all of
the mice were sacrificed and subjected to histomorphometric and micro-
radiographic examinations. The serum level of Ca2+ was measured by
Calcium C (Wako).
Statistical Analysis
All data are expressed as the mean ± SEM (n = 5). Statistical analysis was per-
formed by using Student’s t test or ANOVA followed by Bonferroni test when
applicable (*p < 0.05; **p < 0.01; ***p < 0.005; n.s., not significant). Results
are representative examples of more than four independent experiments. In
Figure 6, statistical analysis was performed between WT and Tec/Btk/
mice (n = 5 per group) on the fold increase of each parameter.
SUPPLEMENTAL DATA
Supplemental Data include six figures and can be found with this article online
at http://www.cell.com/cgi/content/full/132/5/794/DC1/.
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